The expanding role for chromatin and transcription in polyglutamine disease

Current Opinion in Genetics and Development

Volumn 26, Issue , 2014, Pages 96-104

  Mohan, Ryan D ^a   Abmayr, Susan M ^a   Workman, Jerry L ^a  

^a STOWERS INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 1 PROTEIN; ATAXIN 2 PROTEIN; ATAXIN 3; BRAIN DERIVED NEUROTROPHIC FACTOR; METHYL CPG BINDING PROTEIN 2; NUCLEIC ACID BINDING PROTEIN; POLYGLUTAMINE; UNCLASSIFIED DRUG; CHROMATIN; PEPTIDE; PROTEIN BINDING; ANDROGEN RECEPTOR; ATAXIN 1; ATAXIN 2; ATAXIN 7; ATROPHIN 1; HUNTINGTIN; TATA BINDING PROTEIN; TRANSCRIPTION FACTOR; VOLTAGE DEPENDENT ANION CHANNEL; VOLTAGE DEPENDENT CALCIUM CHANNEL SUBUNIT ALPHA 1A;

CAUSAL ATTRIBUTION; CHROMATIN; DENTATORUBROPALLIDOLUYSIAN ATROPHY; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC DISORDER; HISTONE METHYLATION; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; MACHADO JOSEPH DISEASE; NONHUMAN; OXIDATIVE STRESS; POLYGLUTAMINE DISEASE; PRIORITY JOURNAL; REVIEW; SPINOCEREBELLAR ATAXIA 17; SPINOCEREBELLAR ATAXIA 2; SPINOCEREBELLAR ATAXIA 6; SPINOCEREBELLAR ATAXIA 7; SPINOCEREBELLAR DEGENERATION; TRANSCRIPTION REGULATION; BIOLOGICAL MODEL; DEGENERATIVE DISEASE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; TRINUCLEOTIDE REPEAT; AMYOTROPHIC LATERAL SCLEROSIS; CAG REPEAT; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASE ASSOCIATION; DISEASE COURSE; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; GENE PRODUCT; GENETIC RISK; PROTEIN ANALYSIS; PROTEIN FUNCTION;

CHROMATIN; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, GENETIC; NEURODEGENERATIVE DISEASES; PEPTIDES; PROTEIN BINDING; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84907343952     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2014.06.008     Document Type: Review

References (71)

1. Friedrich B., Euler P., Ziegler R., Kuhn A., Landwehrmeyer B.G., Luthi-Carter R., Weiller C., Hellwig S., Zucker B. Comparative analyses of Purkinje cell gene expression profiles reveal shared molecular abnormalities in models of different polyglutamine diseases. Brain Res 2012, 1481:37-48.
2. Gatchel J.R., Watase K., Thaller C., Carson J.P., Jafar-Nejad P., Shaw C., Zu T., Orr H.T., Zoghbi H.Y. The insulin-like growth factor pathway is altered in spinocerebellar ataxia type 1 and type 7. Proc Natl Acad Sci U S A 2008, 105:1291-1296.
3. Seidel K., Siswanto S., Brunt E.R., den Dunnen W., Korf H.W., Rub U. Brain pathology of spinocerebellar ataxias. Acta Neuropathol 2012, 124:1-21.
4. Margulis B.A., Vigont V., Lazarev V.F., Kaznacheyeva E.V., Guzhova I.V. Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors. FEBS Lett 2013, 587:1997-2007.
5. Kazantsev A., Preisinger E., Dranovsky A., Goldgaber D., Housman D: Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc Natl Acad Sci 1999, 96:11404-11409.
6. Gatchel J.R., Zoghbi H.Y. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet 2005, 6:743-755.
7. Holmberg M., Duyckaerts C., Dürr A., Cancel G., Gourfinkel-An I., Damier P., Faucheux B., Trottier Y., Hirsch E.C., Agid Y., et al. Spinocerebellar Ataxia Type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum Mol Genet 1998, 7:913-918.
8. Huynh D.P., Del Bigio M.R., Ho D.H., Pulst S.-M. Expression of ataxin-2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2. Ann Neurol 1999, 45:232-241.
9. Chai Y., Shao J., Miller V.M., Williams A., Paulson H.L. Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc Natl Acad Sci 2002, 99:9310-9315.
10. Luthi-Carter R., Strand A.D., Hanson S.A., Kooperberg C., Schilling G., La Spada A.R., Merry D.E., Young A.B., Ross C.A., Borchelt D.R., et al. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum Mol Genet 2002, 11:1927-1937.
11. MacDonald M.E., Ambrose C.M., Duyao M.P., Myers R.H., Lin C., Srinidhi L., Barnes G., Taylor S.A., James M., Groot N., et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
12. Augood S.J., Faull R.L., Love D.R., Emson P.C. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience 1996, 72:1023-1036.
13. Bowles K.R., Brooks S.P., Dunnett S.B., Jones L. Gene expression and behaviour in mouse models of HD. Brain Res Bull 2012, 88:276-284.
14. Dunah A.W., Jeong H., Griffin A., Kim Y.-M., Standaert D.G., Hersch S.M., Mouradian M.M., Young A.B., Tanese N., Krainc D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002, 296:2238-2243.
15. Steffan J.S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y.-Z., Gohler H., Wanker E.E., Bates G.P., Housman D.E., Thompson LM: The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci 2000, 97:6763-6768.
16. Soldati C., Bithell A., Johnston C., Wong K.Y., Stanton L.W., Buckley N.J. Dysregulation of REST-regulated coding and non-coding RNAs in a cellular model of Huntington's disease. J Neurochem 2013, 124:418-430.
17. Cong S.Y., Pepers B.A., Evert B.O., Rubinsztein D.C., Roos R.A., van Ommen G.J., Dorsman J.C. Mutant huntingtin represses CBP, but not p300, by binding and protein degradation. Mol Cell Neurosci 2005, 30:12-23.
18. Rada-Iglesias A., Bajpai R., Swigut T., Brugmann S.A., Flynn R.A., Wysocka J. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 2011, 470:279-283.
19. Nucifora F.C., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V.L., et al. Interference by Huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science 2001, 291:2423-2428.
20. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., et al. Loss of Huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.
21. McFarland K.N., Huizenga M.N., Darnell S.B., Sangrey G.R., Berezovska O., Cha J.H., Outeiro T.F., Sadri-Vakili G. MeCP2: a novel Huntingtin interactor. Hum Mol Genet 2014, 23:1036-1044.
22. Ryu H., Lee J., Hagerty S.W., Soh B.Y., McAlpin S.E., Cormier K.A., Smith K.M., Ferrante R.J. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc Natl Acad Sci U S A 2006, 103:19176-19181.
23. La Spada A.R., Wilson E.M., Lubahn D.B., Harding A.E., Fischbeck K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991, 352:77-79.
24. Kang Z., Janne O.A., Palvimo J.J. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 2004, 18:2633-2648.
25. Yazawa I., Nukina N., Hashida H., Goto J., Yamada M., Kanazawa I. Abnormal gene product identified in hereditary dentatorubral-pallidoluysian atrophy (DRPLA) brain. Nat Genet 1995, 10:99-103.
26. Takahashi H., Egawa S., Piao Y.-S., Hayashi S., Yamada M., Shimohata T., Oyanagi K., Tsuji S. Neuronal nuclear alterations in dentatorubral-pallidoluysian atrophy: ultrastructural and morphometric studies of the cerebellar granule cells. Brain Res 2001, 919:12-19.
27. Wang L., Tsai C.C. Atrophin proteins: an overview of a new class of nuclear receptor corepressors. Nucl Recept Signal 2008, 6:e009.
28. Wood J.D., Nucifora F.C., Duan K., Zhang C., Wang J., Kim Y., Schilling G., Sacchi N., Liu J.M., Ross C.A. Atrophin-1, the dentato-rubral and pallido-luysian atrophy gene product, interacts with ETO/MTG8 in the nuclear matrix and represses transcription. J Cell Biol 2000, 150:939-948.
29. Hu H., Columbus J., Zhang Y., Wu D., Lian L., Yang S., Goodwin J., Luczak C., Carter M., Chen L., et al. A map of WW domain family interactions. Proteomics 2004, 4:643-655.
30. Chen C., Matesic L.E. The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev 2007, 26:587-604.
31. Wood J.D., Yuan J., Margolis R.L., Colomer V., Duan K., Kushi J., Kaminsky Z., Kleiderlein J.J., Sharp A.H., Ross C.A. Atrophin-1, the DRPLA gene product, interacts with two families of WW domain-containing proteins. Mol Cell Neurosci 1998, 11:149-160.
32. Lim J., Hao T., Shaw C., Patel A.J., Szabo G., Rual J.F., Fisk C.J., Li N., Smolyar A., Hill D.E., et al. A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell 2006, 125:801-814.
33. Bergeron D., Lapointe C., Bissonnette C., Tremblay G., Motard J., Roucou X. An out-of-frame overlapping reading frame in the ataxin-1 coding sequence encodes a novel ataxin-1 interacting protein. J Biol Chem 2013, 288:21824-21835.
34. Fernandez-Funez P., Nino-Rosales M.L., de Gouyon B., She W.C., Luchak J.M., Martinez P., Turiegano E., Benito J., Capovilla M., Skinner P.J., et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 2000, 408:101-106.
35. Tong X., Gui H., Jin F., Heck B.W., Lin P., Ma J., Fondell J.D., Tsai C.C. Ataxin-1 and Brother of ataxin-1 are components of the Notch signalling pathway. EMBO Rep 2011, 12:428-435.
36. Okazawa H., Rich T., Chang A., Lin X., Waragai M., Kajikawa M., Enokido Y., Komuro A., Kato S., Shibata M., et al. Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death. Neuron 2002, 34:701-713.
37. Sanchez I., Pinol P., Corral-Juan M., Pandolfo M., Matilla-Duenas A. A novel function of Ataxin-1 in the modulation of PP2A activity is dysregulated in the spinocerebellar ataxia type 1. Hum Mol Genet 2013, 22:3425-3437.
38. Nowak S.J., Pai C.Y., Corces V.G. Protein phosphatase 2A activity affects histone H3 phosphorylation and transcription in Drosophila melanogaster. Mol Cell Biol 2003, 23:6129-6138.
39. Elden A.C., Kim H.J., Hart M.P., Chen-Plotkin A.S., Johnson B.S., Fang X., Armakola M., Geser F., Greene R., Lu M.M., et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010, 466:1069-1075.
40. Van Damme P., Veldink J.H., van Blitterswijk M., Corveleyn A., van Vught P.W., Thijs V., Dubois B., Matthijs G., van den Berg L.H., Robberecht W. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology 2011, 76:2066-2072.
41. Shibata H., Huynh D.P., Pulst S-M: A novel protein with RNA-binding motifs interacts with ataxin-2. Hum Mol Genet 2000, 9:1303-1313.
42. Nonhoff U., Ralser M., Welzel F., Piccini I., Balzereit D., Yaspo M.L., Lehrach H., Krobitsch S. Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol Biol Cell 2007, 18:1385-1396.
43. Satterfield T.F., Pallanck L.J. Ataxin-2 and its Drosophila homolog, ATX2, physically assemble with polyribosomes. Hum Mol Genet 2006, 15:2523-2532.
44. Lim C., Allada R: ATAXIN-2 activates period translation to sustain circadian rhythms in Drosophila. Science 2013, 340:875-879.
45. Zhang Y., Ling J., Yuan C., Dubruille R., Emery P. A role for Drosophila ATX2 in activation of PER translation and Circadian behavior. Science 2013, 340:879-882.
46. Jardim L.B., Silveira I., Pereira M.L., Ferro A., Alonso I., do Ceu Moreira M., Mendonca P., Ferreirinha F., Sequeiros J., Giugliani R. A survey of spinocerebellar ataxia in South Brazil-66 new cases with Machado-Joseph disease, SCA7, SCA8, or unidentified disease-causing mutations. J Neurol 2001, 248:870-876.
47. Evert B.O., Araujo J., Vieira-Saecker A.M., de Vos R.A., Harendza S., Klockgether T., Wullner U. Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. J Neurosci 2006, 26:11474-11486.
48. Nicastro G., Todi S.V., Karaca E., Bonvin A.M., Paulson H.L., Pastore A. Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3. PLoS One 2010, 5:e12430.
49. Burnett B.G., Pittman R.N. The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation. Proc Natl Acad Sci U S A 2005, 102:4330-4335.
50. Doss-Pepe E.W., Stenroos E.S., Johnson W.G., Madura K. Ataxin-3 interactions with rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis. Mol Cell Biol 2003, 23:6469-6483.
51. Araujo J., Breuer P., Dieringer S., Krauss S., Dorn S., Zimmermann K., Pfeifer A., Klockgether T., Wuellner U., Evert B.O. FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3. Hum Mol Genet 2011, 20:2928-2941.
52. Du X., Wang J., Zhu H., Rinaldo L., Lamar K.M., Palmenberg A.C., Hansel C., Gomez C.M. Second cistron in CACNA1A gene encodes a transcription factor mediating cerebellar development and SCA6. Cell 2013, 154:118-133.
53. Watase K., Barrett C.F., Miyazaki T., Ishiguro T., Ishikawa K., Hu Y., Unno T., Sun Y., Kasai S., Watanabe M., et al. Spinocerebellar ataxia type 6 knockin mice develop a progressive neuronal dysfunction with age-dependent accumulation of mutant CaV2.1 channels. Proc Natl Acad Sci 2008, 105:11987-11992.
54. Ishiguro T., Ishikawa K., Takahashi M., Obayashi M., Amino T., Sato N., Sakamoto M., Fujigasaki H., Tsuruta F., Dolmetsch R., et al. The carboxy-terminal fragment of α1A calcium channel preferentially aggregates in the cytoplasm of human spinocerebellar ataxia type 6 Purkinje cells. Acta Neuropathol 2010, 119:447-464.
55. 2+ channel α1A subunits translocate to nuclei and promote polyglutamine-mediated toxicity. Hum Mol Genet 2006, 15:1587-1599.
56. Kubodera T., Yokota T., Ohwada K., Ishikawa K., Miura H., Matsuoka T., Mizusawa H. Proteolytic cleavage and cellular toxicity of the human alpha1A calcium channel in spinocerebellar ataxia type 6. Neurosci Lett 2003, 341:74-78.
57. Marquèze-Pouey B., Martin-Moutot N., Sakkou-Norton M., Lévêque C., Ji Y., Cornet V., Hsiao W.L., Seagar M. Toxicity and endocytosis of spinocerebellar ataxia type 6 polyglutamine domains: role of myosin IIB†. Traffic 2008, 9:1088-1100.
58. v 2.1-CTF) aggregate is sufficient to cause cell death. PLoS One 2013, 8:e50121.
59. Weake V.M., Dyer J.O., Seidel C., Box A., Swanson S.K., Peak A., Florens L., Washburn M.P., Abmayr S.M., Workman J.L. Post-transcription initiation function of the ubiquitous SAGA complex in tissue-specific gene activation. Genes Dev 2011, 25:1499-1509.
60. Lang G., Bonnet J., Umlauf D., Karmodiya K., Koffler J., Stierle M., Devys D., Tora L. The tightly controlled deubiquitination activity of the human SAGA complex differentially modifies distinct gene regulatory elements. Mol Cell Biol 2011, 31:3734-3744.
61. Koutelou E., Hirsch C.L., Dent S.Y. Multiple faces of the SAGA complex. Curr Opin Cell Biol 2010, 22:374-382.
62. Samara N.L., Datta A.B., Berndsen C.E., Zhang X., Yao T., Cohen R.E., Wolberger C. Structural insights into the assembly and function of the SAGA deubiquitinating module. Science 2010, 328:1025-1029.
63. Kohler A., Zimmerman E., Schneider M., Hurt E., Zheng N. Structural basis for assembly and activation of the heterotetrameric SAGA histone H2B deubiquitinase module. Cell 2010, 141:606-617.
64. van de Warrenburg B.P., Frenken C.W., Ausems M.G., Kleefstra T., Sinke R.J., Knoers N.V., Kremer H.P. Striking anticipation in spinocerebellar ataxia type 7: the infantile phenotype. J Neurol 2001, 248:911-914.
65. McMahon S.J., Pray-Grant M.G., Schieltz D., Yates J.R., Grant P.A. Polyglutamine-expanded spinocerebellar ataxia-7 protein disrupts normal SAGA and SLIK histone acetyltransferase activity. Proc Natl Acad Sci U S A 2005, 102:8478-8482.
66. Palhan V.B., Chen S., Peng G.H., Tjernberg A., Gamper A.M., Fan Y., Chait B.T., La Spada A.R., Roeder R.G. Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Proc Natl Acad Sci U S A 2005, 102:8472-8477.
67. Burke T.L., Miller J.L., Grant PA: Direct inhibition of Gcn5 protein catalytic activity by polyglutamine-expanded ataxin-7. J Biol Chem 2013, 288:34266-34275.
68. McCullough S.D., Xu X., Dent S.Y., Bekiranov S., Roeder R.G., Grant P.A. Reelin is a target of polyglutamine expanded ataxin-7 in human spinocerebellar ataxia type 7 (SCA7) astrocytes. Proc Natl Acad Sci U S A 2012, 109:21319-21324.
69. Nakamura K., Jeong S.Y., Uchihara T., Anno M., Nagashima K., Nagashima T., Ikeda S., Tsuji S., Kanazawa I. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 2001, 10:1441-1448.
70. Huang S., Ling J.J., Yang S., Li X.J., Li S. Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor. Brain 2011, 134:1943-1958.
71. Friedman M.J., Wang C.E., Li X.J., Li S. Polyglutamine expansion reduces the association of TATA-binding protein with DNA and induces DNA binding-independent neurotoxicity. J Biol Chem 2008, 283:8283-8290.